← Leaderboards
Thomas Hofmann
Qrumpharma, Inc.
$520,306
Attributed
$520,306
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$520,306 · 1
By mechanism
N01$520,306 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAerosolsAnimalsAntitubercular AgentsBangladeshBypassCardiovascular SystemCell LineClinically RelevantCostDrug DevelopmentDrug ResistanceEffectivenessEpithelial CellsFormulationInhalationIn Vitro ModelLeprosyLungMulti-Drug ResistanceNebulizerOralPharmaceutical PreparationsPreclinical Development